Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IVVD

Invivyd Inc

Dec 12 • 02:46PM ET

0.5811

Dollar change -0.0029
Percentage change -0.50	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX MRK JNJ NVAX AZN GSK GILD SNY

| Held by: VTI IWM VXF IWN VTWO IWC VTWV RSSL VTHR UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.95	Insider Own	38.54%	Shs Outstand	119.60M	Perf Week	1.80%
Market Cap	69.51M	Forward P/E	-	EPS next Y	-0.12	Insider Trans	-1.04%	Shs Float	73.52M	Perf Month	-41.89%
Income	-225.14M	PEG	-	EPS next Q	-0.22	Inst Own	56.90%	Short Float	6.60%	Perf Quarter	-49.47%
Sales	11.56M	P/S	6.01	EPS this Y	20.55%	Inst Trans	-18.19%	Short Ratio	8.61	Perf Half Y	-65.82%
Book/sh	0.70	P/B	0.84	EPS next Y	91.83%	ROA	-103.08%	Short Interest	4.85M	Perf Year	-64.35%
Cash/sh	0.89	P/C	0.65	EPS next 5Y	-	ROE	-136.59%	52W Range	0.57 - 5.20	Perf YTD	-85.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-270.01%	52W High	-88.81%	Beta	0.53
Dividend TTM	-	Quick Ratio	1.58	Sales past 5Y	0.00%	Gross Margin	74.00%	52W Low	1.95%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	1.92	EPS Y/Y TTM	-25.72%	Oper. Margin	-2032.16%	RSI (14)	33.74	Volatility	9.97% 10.57%
Employees	94	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-1946.87%	Recom	1.40	Target Price	6.51
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-41.43%	Payout	-	Rel Volume	0.71	Prev Close	0.58
Sales Surprise	-65.87%	EPS Surprise	-51.11%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	563.37K	Price	0.58
SMA20	-12.89%	SMA50	-31.20%	SMA200	-64.84%	Trades		Volume	327,008	Change	-0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)
Nov-14-24 08:20AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.18%
07:05AM	Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:01AM	Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor (GlobeNewswire)
07:27AM	Loading…
Nov-13-24 07:27AM	Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com) -11.00%
Nov-12-24 08:30AM	Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively (GlobeNewswire)
Nov-06-24 08:01AM	Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire) +12.62%
07:01AM	Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:03AM	Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability (GlobeNewswire) -12.80%
07:01AM	Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants (GlobeNewswire)
Oct-16-24 07:01AM	Invivyd to Present PEMGARDA (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 (GlobeNewswire)
Oct-01-24 07:01AM	Invivyd Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data (GlobeNewswire) -11.75%
Sep-23-24 07:01AM	Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart) (GlobeNewswire)
Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
07:01AM	Loading…
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.31% +9.84%
Jul-01-24 07:01AM	Invivyd Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +9.09%
Jun-14-24 07:01AM	Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants (GlobeNewswire) -7.06%
Jun-03-24 04:01PM	Invivyd to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-24 07:05AM	Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies (GlobeNewswire)
07:00AM	Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer (GlobeNewswire)
May-29-24 07:00AM	Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) (GlobeNewswire)
May-22-24 07:00AM	Invivyd Elects Two New Independent Members to its Board of Directors (GlobeNewswire)
04:01PM	Loading…
May-13-24 04:01PM	Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:44AM	Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:25PM	Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com) -6.61%
May-09-24 10:56PM	IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 (InvestorPlace)
04:01PM	Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-07-24 07:30AM	Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback (GlobeNewswire) +6.36%
May-02-24 05:13PM	Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-24 07:30AM	Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position (GlobeNewswire) +6.73%
Apr-15-24 07:30AM	Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA (GlobeNewswire)
Apr-12-24 07:30AM	Invivyd Announces CEO Transition (GlobeNewswire)
Apr-04-24 04:01PM	Invivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million (GlobeNewswire) -8.91% -7.82%
Mar-28-24 01:53PM	IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023 (InvestorPlace) +11.00%
07:00AM	Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-22-24 03:28PM	Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial (GlobeNewswire) +41.10%
03:04PM	Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 (GlobeNewswire)
Feb-05-24 04:02PM	Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace) +11.31%
Jan-12-24 12:00PM	All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy (Zacks)
Jan-03-24 07:00AM	Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents (GlobeNewswire)
Dec-23-23 05:29AM	Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy? (Motley Fool)
Dec-19-23 11:52AM	Invivyd (IVVD) Surges on Positive Data From COVID-19 Study (Zacks) -7.52%
Dec-18-23 07:00AM	Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 (GlobeNewswire) +120.25%
Nov-13-23 10:21AM	Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Nov-10-23 08:35AM	Q3 2023 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:01PM	Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -7.89%
Nov-02-23 04:01PM	Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +5.44%
Oct-31-23 04:01PM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.96%
Sep-11-23 07:00AM	Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 (GlobeNewswire)
Sep-06-23 08:17PM	7 Biotech Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
07:00AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 07:00AM	Invivyd Appoints William Duke as Chief Financial Officer (GlobeNewswire)
Aug-29-23 01:13PM	Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why (Zacks)
Aug-15-23 05:45AM	Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:43AM	Q2 2023 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:01PM	Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-03-23 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jul-27-23 04:01PM	Invivyd Announces Appointment of Sara Cotter to Board Of Directors (GlobeNewswire)
Jul-17-23 02:15PM	Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People (Benzinga)
07:00AM	Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People (GlobeNewswire)
Jun-26-23 07:00AM	Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19 (GlobeNewswire)
Jun-22-23 01:07PM	Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19 (Benzinga) -6.19%
07:00AM	Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People (GlobeNewswire)
Jun-01-23 07:00AM	Invivyd to Participate at the Jefferies Healthcare Conference (GlobeNewswire) -16.67%
May-23-23 06:25AM	Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +19.72%
May-11-23 04:01PM	Invivyd Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 04:01PM	Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-25-23 04:01PM	Invivyd to Participate at H.C. Wainwrights BioConnect Investor Conference (GlobeNewswire)
07:00AM	Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update (GlobeNewswire)
Apr-14-23 09:35AM	After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD) (Zacks)
Apr-12-23 07:00AM	Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer (GlobeNewswire)
Mar-30-23 04:01PM	Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19 (GlobeNewswire) -8.14%
Mar-28-23 04:58AM	Invivyd, Inc. (NASDAQ:IVVD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:41AM	Full Year 2022 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) -8.39%
Mar-23-23 04:01PM	Invivyd Reports Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-22-23 04:30PM	Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19 (GlobeNewswire) -9.55%
Mar-16-23 07:00AM	Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 07:00AM	Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies (GlobeNewswire)
Feb-28-23 07:00AM	Invivyd to Participate at Cowens 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-03-23 07:30AM	Invivyd Announces Changes to Executive Team (GlobeNewswire) -7.89%
Jan-27-23 05:59PM	Why Shares of Invivyd Jumped This Week (Motley Fool) -8.47%
Jan-02-23 12:00PM	Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why (Zacks)
Dec-19-22 07:00AM	Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop (GlobeNewswire)
Dec-13-22 02:37PM	We Think Invivyd (NASDAQ:IVVD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-06-22 04:01PM	Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer (GlobeNewswire) -8.45% +5.90%
Nov-22-22 09:20PM	The Petri Dish: J&J vet joins Moderna as U.S. GM; Invivyd partners with investment firm (American City Business Journals)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
07:00AM	Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19 (GlobeNewswire)
Nov-10-22 04:01PM	Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +7.55%
Nov-09-22 07:00AM	Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -9.07%
Nov-02-22 07:00AM	Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -9.88%

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGUIRE TERRANCE	Director	Dec 10 '24	Sale	0.59	175,000	103,005	4,363,079	Dec 11 06:26 PM
MCGUIRE TERRANCE	Director	Dec 11 '24	Sale	0.59	160,400	94,812	4,202,679	Dec 11 06:26 PM
MCGUIRE TERRANCE	Director	Dec 09 '24	Sale	0.61	150,000	91,560	4,538,079	Dec 11 06:26 PM
POLARIS PARTNERS IX, LP	Director	Dec 09 '24	Proposed Sale	0.61	1,000,000	610,400		Dec 09 04:27 PM
MCGUIRE TERRANCE	Director	May 29 '24	Sale	1.66	112,381	186,575	4,688,079	May 31 05:09 PM
Adimab, LLC	10% Owner	Jan 19 '24	Sale	3.95	5,000,000	19,750,000	21,687,906	Jan 22 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVVD

Invivyd Inc

Upgrade your FINVIZ experience